Legal & General Group Plc lifted its stake in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 37.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 190,748 shares of the company’s stock after purchasing an additional 51,704 shares during the period. Legal & General Group Plc’s holdings in Artivion were worth $8,700,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the third quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd boosted its holdings in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas boosted its holdings in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares in the last quarter. Finally, KBC Group NV acquired a new position in Artivion in the fourth quarter valued at approximately $65,000. 86.37% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the company. Canaccord Genuity Group lowered their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Stifel Nicolaus set a $45.00 price target on Artivion in a report on Monday. Citizens Jmp lowered their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, April 10th. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.17.
Artivion Price Performance
Artivion stock opened at $20.80 on Friday. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The business has a 50 day simple moving average of $30.74 and a 200-day simple moving average of $38.01. The stock has a market capitalization of $1.01 billion, a PE ratio of 86.68 and a beta of 1.26.
Artivion Company Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Further Reading
- Five stocks we like better than Artivion
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
